康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03759 康龙化成

已收盘 05-03 16:09:00

9.950

-0.530

-5.06%

最高10.840	最低9.840	成交量127.22万
今开10.840	昨收10.480	日振幅9.54%
总市值177.85亿	流通市值30.00亿	总股本17.87亿
成交额1,273万	换手率0.42%	流通股本3.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03759","market":"HK","secType":"STK","nameCN":"康龙化成","latestPrice":9.95,"timestamp":1714723740032,"preClose":10.48,"halted":0,"volume":1272150,"delay":0,"floatShares":301537125,"shares":1787394297,"eps":0.9816084,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.53,"latestTime":"05-03 16:09:00","open":10.84,"high":10.84,"low":9.84,"amount":12731624,"amplitude":0.09542,"askPrice":9.95,"askSize":700,"bidPrice":9.94,"bidSize":7200,"shortable":3,"etf":0,"ttmEps":0.9073026141870135,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1574870400000,"adjPreClose":10.48,"dividendRate":0.021809,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.312399,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300759","market":"SZ","secType":"STK","nameCN":"康龙化成","latestPrice":19.75,"timestamp":1714460589000,"preClose":19.95,"halted":0,"volume":18590333,"delay":0,"premium":"-53.64"}},"requestUrl":"/m/hq/s/03759/","defaultTab":"news","newsList":[{"id":"2432181529","title":"港股异动 | CRO概念股全线回落 药明康德(02359)跌超7%领跌 公司首季利润率不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2432181529","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432181529?lang=zh_cn&edition=full","pubTime":"2024-05-03 11:26","pubTimestamp":1714706785,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股全线回落，截至发稿，药明康德跌6.47%，报36.15元；凯莱英跌5.33%，报63.05元；康龙化成跌4.96%，报9.96港元；泰格医药跌3.23%，报34.5港元。消息面上，药明康德2024年一季度实现营业收入79.82亿元，同比减少10.95%；归母净利润19.42亿元，同比减少10.42%。浦银国际指出，药明康德1Q24经调整Non-IFRS归母净利润低于预期。公司早期业务受行业融资疲软影响，考虑到降息预期已进一步推迟至2024年底，该行对早期业务收入增速持较为保守态度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117040.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432992248","title":"康龙化成盘中异动 股价大跌5.07%报9.950港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432992248","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432992248?lang=zh_cn&edition=full","pubTime":"2024-05-03 10:37","pubTimestamp":1714703842,"startTime":"0","endTime":"0","summary":"2024年05月03日早盘10时37分，康龙化成股票出现波动，股价大幅跳水5.07%。截至发稿，该股报9.950港元/股，成交量40.975万股，换手率0.14%，振幅8.59%。康龙化成股票所在的药品行业中，整体跌幅为0.14%。其相关个股中，开拓药业-B、东瑞制药、中生联合涨幅较大，振幅较大的相关个股有中生联合、衍生集团、康龙化成，振幅分别为15.31%、9.68%、8.40%。)消息层面，截至10时37分，康龙化成股票正面舆情新闻比例28.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405031037227a57f502&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405031037227a57f502&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432992594","title":"康龙化成(03759)下跌5.15%，报9.94元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432992594","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432992594?lang=zh_cn&edition=full","pubTime":"2024-05-03 10:37","pubTimestamp":1714703839,"startTime":"0","endTime":"0","summary":"5月3日，康龙化成(03759)盘中下跌5.15%，截至10:37，报9.94元/股，成交417.35万元。康龙化成是一家国际领先的生命科学研发服务企业，主要为小分子、大分子和细胞与基因治疗药物的研发提供全流程的研发生产服务。公司在中国、美国、英国开展运营，拥有14,000多名员工，服务的主要市场包括北美、欧洲、日本和中国。截至2024年一季报，康龙化成营业总收入26.71亿元、净利润2.31亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/03103740513578.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432618955","title":"CRO概念股早盘普涨 药明康德涨超6%康龙化成涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432618955","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2432618955?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:34","pubTimestamp":1714620872,"startTime":"0","endTime":"0","summary":"CRO概念股早盘普涨，药明康德（02359）上涨6.49%，报37.75港元；康龙化成（03759）上涨5.25%，报10.22港元；药明生物（02269）上涨5.24%，报14.46港元；金斯瑞生物科技（01548）上涨3.44%，报12.04港元。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-02/doc-inatvexf7589255.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-02/doc-inatvexf7589255.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432974616","title":"港股异动 | CRO概念股早盘普涨 美联储加息预期逐步减弱 创新药投融资环境有望逐步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2432974616","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432974616?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:12","pubTimestamp":1714619577,"startTime":"0","endTime":"0","summary":"消息面上，美联储5月会议维持利率不变，鲍威尔也否定了加息选项，同时宣布缩表即将减速。湘财证券指出，虽然当前CXO受国内外医药投融资下滑影响业绩承压，但鉴于美联储加息预期逐步减弱，以及经过近两年全球biotech领域估值泡沫的出清，全球生技产业性价比已凸显，创新药投融资环境有望逐步回暖，看好CXO长期向好的短期改善。“生物制造”已经被写入2024年政府工作报告并被列为新增长引擎之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116838.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432692584","title":"康龙化成盘中异动 股价大涨5.04%报10.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432692584","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432692584?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:51","pubTimestamp":1714618297,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘10时51分，康龙化成股票出现波动，股价急速上涨5.04%。截至发稿，该股报10.200港元/股，成交量38.44万股，换手率0.13%，振幅8.24%。资金方面，该股资金流入174.464万港元，流出123.148万港元。机构评级方面，在所有12家参与评级的机构中，75%的券商给予买入建议，17%的券商给予持有建议，8%的券商给予卖出建议。康龙化成股票所在的药品行业中，整体涨幅为0.27%。)消息层面，截至10时51分，康龙化成股票正面舆情新闻比例35.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021051377925aaf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021051377925aaf0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431630038","title":"康龙化成(03759)拟回购2亿-3亿元A股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2431630038","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431630038?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:32","pubTimestamp":1714397550,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康龙化成 公布，鉴于截至 2024 年 4 月 19 日公司A 股股票连续 20 个交易日内股票收盘价格跌幅累计超过 20%，为维护公司价值及股东权益所必需，切实推动“质量回报双提升”行动方案的实施，公司拟使用自有资金以集中竞价交易方式回购公司部分人民币普通股 A 股股份。本次回购资金总额为不低于人民币 2 亿元且不超过人民币 3 亿元，回购价格上限不超过人民币 31 元/股(含)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115156.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431393468","title":"康龙化成获开源证券买入评级，2024Q1业绩阶段性承压，新业务推进打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2431393468","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431393468?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:51","pubTimestamp":1714387909,"startTime":"0","endTime":"0","summary":"4月29日，康龙化成获开源证券买入评级，近一个月康龙化成获得13份研报关注。研报认为，2024Q1，公司实现营收26.71亿元，同比下滑1.95%；实现归母净利润2.31亿元，同比下滑33.80%。利润端短期承压，主要系2024Q1营业收入阶段性下滑，营业成本、期间费用同比增加综合所致。我们看好公司长期发展，维持原盈利预测，鉴于公司各业务板块协同效应持续增强，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042918515187bee2f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042918515187bee2f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431836180","title":"开源证券：给予康龙化成买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431836180","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431836180?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:21","pubTimestamp":1714386075,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,汪晋近期对康龙化成进行研究并发布了研究报告《公司信息更新报告：2024Q1业绩阶段性承压，新业务推进打开成长空间》，本报告对康龙化成给出买入评级，当前股价为19.95元。截至2023年底，已为26个CGT项目提供分析测试服务，为13个基因治疗项目提供CDMO服务。最新盈利预测明细如下：该股最近90天内共有22家机构给出评级，买入评级17家，增持评级4家，中性评级1家；过去90天内机构目标均价为25.27。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900024323.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431502926","title":"浦银国际证券：给予康龙化成中性评级，目标价位22.4元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431502926","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431502926?lang=zh_cn&edition=full","pubTime":"2024-04-29 11:05","pubTimestamp":1714359930,"startTime":"0","endTime":"0","summary":"浦银国际证券有限公司胡泽宇,阳景近期对康龙化成进行研究并发布了研究报告《1Q24业绩不及预期，但新签订单增速超预期》，本报告对康龙化成给出中性评级，认为其目标价位为22.40元，当前股价为19.98元，预期上涨幅度为12.11%。　　康龙化成　　有”评级，略微下调目标价至22.4元。维持A股“持有”评级，给予A股目标价较港股目标价60%的溢价，对应A股目标价人民币22.4元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900007555.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431702579","title":"港股异动 | CRO概念股延续反弹 下游需求端有待好转 国内CXO公司仍具备竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2431702579","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431702579?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:55","pubTimestamp":1714359352,"startTime":"0","endTime":"0","summary":"中信建投指出，目前医药领域一级投融资仍有待恢复，下游需求端有待好转。该行指出，国内CXO公司相比全球企业仍具备一定竞争优势，近年来在ADC、多肽药物快速发展下，相关CXO需求迅速增加，小核酸、CGT等细分领域也有望迎来快速发展。临床CRO领域匹配高端需求的公司有望获得更高份额。目前CXO板块整体估值处于低位，长期来看，我们仍旧看好CXO板块发展潜力及成长空间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113909.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431028481","title":"康龙化成(03759)上涨5.06%，报9.96元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431028481","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431028481?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:22","pubTimestamp":1714357365,"startTime":"0","endTime":"0","summary":"4月29日，康龙化成(03759)盘中上涨5.06%，截至10:22，报9.96元/股，成交1752.81万元。康龙化成是一家国际领先的生命科学研发服务企业，主要为小分子、大分子和细胞与基因治疗药物的研发提供全流程的研发生产服务。公司在中国、美国、英国开展运营，拥有14,000多名员工，服务的主要市场包括北美、欧洲、日本和中国。截至2024年一季报，康龙化成营业总收入26.71亿元、净利润2.31亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29102240459718.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431028371","title":"康龙化成盘中异动 大幅拉升5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431028371","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431028371?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:22","pubTimestamp":1714357358,"startTime":"0","endTime":"0","summary":"2024年04月29日早盘10时22分，康龙化成股票出现异动，股价大幅上涨5.06%。截至发稿，该股报9.961港元/股，成交量180.105万股，换手率0.60%，振幅5.06%。康龙化成股票所在的药品行业中，整体涨幅为0.33%。)消息层面，截至10时22分，康龙化成股票正面舆情新闻比例30%。《康龙化成获信达证券买入评级，新签订单同比增长20%+，全年有望逐渐回暖》资讯为影响康龙化成的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291022387a56e45f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291022387a56e45f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431583042","title":"南向资金4月26日净卖出康龙化成0.43万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431583042","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431583042?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:31","pubTimestamp":1714354292,"startTime":"0","endTime":"0","summary":"4月26日，南向资金减持康龙化成0.43万股连续3日减持。截止当日收盘，港股通共持有康龙化成15631.49万股，占流通股51.83%。康龙化成近5个交易日上涨12.99%，港股通累计减持193.87万股；近20个交易日上涨1.07%，港股通累计增持472.63万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909474587bcb43e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909474587bcb43e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431423970","title":"康龙化成4月26日获北向资金加仓207.18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431423970","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431423970?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:31","pubTimestamp":1714354277,"startTime":"0","endTime":"0","summary":"4月26日, 北向资金增持康龙化成207.18万股。截止当日收盘，深股通共持有康龙化成3059.53万股，占流通股2.05%。康龙化成近5个交易日上涨5.39%，深股通累计增持228.59万股；近20个交易日下跌5.15%，深股通累计增持48.73万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909443887bcb0ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909443887bcb0ba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430032139","title":"康龙化成获信达证券买入评级，新签订单同比增长20%+，全年有望逐渐回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2430032139","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430032139?lang=zh_cn&edition=full","pubTime":"2024-04-28 18:11","pubTimestamp":1714299102,"startTime":"0","endTime":"0","summary":"4月28日，康龙化成获信达证券买入评级，近一个月康龙化成获得11份研报关注。研报认为，公司业务整合影响利润率表现，费用率小幅上升。行业环境遇冷致业绩承压，多指标释放复苏信号。新签订单同比增长20%+，支撑长期稳定发展。2023年，公司新增客户800余家，活跃客户2800余家，海外业务收入增长27.5%，欧洲客户加速增长，增速24.4%，海外市场收入贡献持续保持较高增速。2024Q1，在公司优质的技术、服务能力支持下，公司新签订单增速同比获20%增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281811438b5d896b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281811438b5d896b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430808390","title":"康龙化成：4月26日接受机构调研，高盛证券、海通证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2430808390","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430808390?lang=zh_cn&edition=full","pubTime":"2024-04-28 16:05","pubTimestamp":1714291520,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年4月28日康龙化成发布公告称公司于2024年4月26日接受机构调研，高盛证券、海通证券、中信建投、广发证券、中信证券、国金证券、兴业证券、中欧基金、汇丰晋信、汇添富基金、华夏基金、华泰证券、嘉实基金、华泰资产、信达澳银、天弘基金、鹏华基金、国盛证券、浙商证券、中金证券、长江证券、招商证券、野村证券、招商国际参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800003505.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430081324","title":"康龙化成：目前没有看到生物医药法案对获客的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2430081324","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430081324?lang=zh_cn&edition=full","pubTime":"2024-04-28 14:56","pubTimestamp":1714287375,"startTime":"0","endTime":"0","summary":"康龙化成在与机构投资者的电话会议中表示，截至目前，没有看到生物医药法案对获客的影响，与客户沟通也没有受到法案的影响。通过当前客户访问量和在手订单角度观察，过去1—2个月很多海外客户来访审计，海外healthcare客户的回暖是非常明显的状态。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404283062562883.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430081237","title":"康龙化成：实现实验室服务在上海和宁波/北京的整合，新的采购订单增加20%以上，预计2024年收入增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430081237","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430081237?lang=zh_cn&edition=full","pubTime":"2024-04-28 14:54","pubTimestamp":1714287262,"startTime":"0","endTime":"0","summary":"金融界4月28日消息， 康龙化成 披露投资者关系活动记录表显示，公司实现了实验室服务在上海和宁波/北京的整合，以实现规模经济。由于关闭上海的实验室，产生了一次性损失。与2023年第一季度相比，劳动力成本增加，主要是由于2023年下半年新增的员工。2023年第一季度有生物资产公允价值变动收益，但2024年第一季度没有。金融成本增加。新的采购订单增加了20%以上，预计2024年的收入增长将保持在10%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042815002487b9c9d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042815002487b9c9d7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430812580","title":"康龙化成：一季度新签订单同比增长超过20%，拟回购A股股份总金额不低于2亿元且不超过3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430812580","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430812580?lang=zh_cn&edition=full","pubTime":"2024-04-28 14:37","pubTimestamp":1714286258,"startTime":"0","endTime":"0","summary":"康龙化成 披露投资者关系活动记录表显示，2024年一季度，公司新签订单同比增长超过20%，其中实验室服务新签订单同比增长超过10%，CMC服务新签订单同比增长超过40%。公司一季度利润下滑，主要是由于收入阶段性下降，叠加其他一些因素所致。公司经营性现金流表现强劲，而且回购可转债的资金已经到位，为维护公司价值及股东权益，公司拟使用自有资金，以集中竞价交易方式回购公司部分A股股票，回购总金额不低于2亿元且不超过3亿元，本次回购股份后拟全部予以注销，并相应减少公司注册资本。同时，公司拟提请股东大会进行一般性授权，同比例回购公司H股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042814503587b9c1cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042814503587b9c1cb&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharmaron.com","stockEarnings":[{"period":"1week","weight":0.1909},{"period":"1month","weight":0.1209},{"period":"3month","weight":0.1466},{"period":"6month","weight":-0.4653},{"period":"1year","weight":-0.5478},{"period":"ytd","weight":-0.3375}],"compareEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.0753},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0307},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":0.068}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康龙化成（北京）新药技术股份有限公司是一家在发现、开发及制造小分子药物、细胞疗法及基因疗法的过程中提供研究及制造服务组合，以及提供医疗工具及临床研究测试服务的中国公司。该公司运营四个业务分部。实验室服务分部包括实验室化学、药物代谢及药代动力学╱吸收、分布、代谢及排泄、生物学、安全评估及发现生物制剂服务。临床开发服务分部包括临床研究、现场管理组织、监管生物分析及放射性标记科学服务。化学、制造及控制服务分部包括工艺开发及制造、材料科学╱预制剂、制剂开发及制造以及分析开发及商业生产服务。该公司还运营其他分部。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.039131},{"month":2,"riseRate":0.4,"avgChangeRate":-0.057339},{"month":3,"riseRate":0.4,"avgChangeRate":-0.053581},{"month":4,"riseRate":1,"avgChangeRate":0.081029},{"month":5,"riseRate":0.6,"avgChangeRate":0.011112},{"month":6,"riseRate":0.75,"avgChangeRate":0.122446},{"month":7,"riseRate":0.5,"avgChangeRate":-0.010338},{"month":8,"riseRate":0.5,"avgChangeRate":-0.010538},{"month":9,"riseRate":0.5,"avgChangeRate":-0.058648},{"month":10,"riseRate":0.5,"avgChangeRate":-0.059073},{"month":11,"riseRate":0.5,"avgChangeRate":0.120922},{"month":12,"riseRate":0.6,"avgChangeRate":0.046864}],"exchange":"SEHK","name":"康龙化成","nameEN":"PHARMARON"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康龙化成(03759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康龙化成,03759,康龙化成股票,康龙化成股票老虎,康龙化成股票老虎国际,康龙化成行情,康龙化成股票行情,康龙化成股价,康龙化成股市,康龙化成股票价格,康龙化成股票交易,康龙化成股票购买,康龙化成股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康龙化成(03759)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康龙化成(03759)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}